{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"17000","value":"4970"},{"groupId":"OG001","spread":"2620","value":"1780"},{"groupId":"OG002","spread":"24100","value":"23400"}]}],"title":"IL-6: Cycle 1 Week 1 (N=31, 13, 5)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"844","value":"526"},{"groupId":"OG001","spread":"2370","value":"892"},{"groupId":"OG002","spread":"68.0","value":"40.4"}]}],"title":"IL-6: Cycle 2 Week 1 (N=4, 14, 5)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"710","value":"562"},{"groupId":"OG001","spread":"2030","value":"1400"},{"groupId":"OG002","spread":"1720","value":"3170"}]}],"title":"IL-10: Cycle 1 Week 1 (N=31, 13, 5)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"497","value":"519"},{"groupId":"OG001","spread":"692","value":"432"},{"groupId":"OG002","spread":"308","value":"277"}]}],"title":"IL-10: Cycle 2 Week 1 (N=4, 14, 5)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"516","value":"207"},{"groupId":"OG001","spread":"1240","value":"539"},{"groupId":"OG002","spread":"1540","value":"2260"}]}],"title":"IFN-ɣ: Cycle 1 Week 1 (N=31, 13, 5)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"65.6","value":"51.8"},{"groupId":"OG001","spread":"51.5","value":"47.6"},{"groupId":"OG002","spread":"28.6","value":"22.8"}]}],"title":"IFN-ɣ: Cycle 2 Week 1 (N=4, 14, 5)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23","value":"22.7"},{"groupId":"OG001","spread":"150","value":"93.9"},{"groupId":"OG002","spread":"1390","value":"900"}]}],"title":"IL-2: Cycle 1 Week 1 (N=31, 13, 5)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.00","value":"10.0"},{"groupId":"OG001","spread":"8.84","value":"14.3"},{"groupId":"OG002","spread":"0.00","value":"10.0"}]}],"title":"IL-2: Cycle 2 Week 1 (N=4, 14, 5)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"241","value":"87.3"},{"groupId":"OG001","spread":"127","value":"60.2"},{"groupId":"OG002","spread":"306","value":"285"}]}],"title":"TNF-α: Cycle 1 Week 1 (N=31, 13, 5)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.00","value":"10.0"},{"groupId":"OG001","spread":"0.00","value":"10.0"},{"groupId":"OG002","spread":"0.00","value":"10.0"}]}],"title":"TNF-α: Cycle 2 Week 1 (N=4, 14, 5)"},{"categories":[{"measurements":[{"comment":"Serum IL-4 levels were below detection limit (\\< 20 pg/mL) in all participants studied.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Serum IL-4 levels were below detection limit (\\< 20 pg/mL) in all participants studied.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Serum IL-4 levels were below detection limit (\\< 20 pg/mL) in all participants studied.","groupId":"OG002","spread":"NA","value":"NA"}]}],"title":"IL-4: Cycle 1 Week 1 (N=0, 0, 0)"},{"categories":[{"measurements":[{"comment":"Serum IL-4 levels were below detection limit (\\< 20 pg/mL) in all participants studied.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Serum IL-4 levels were below detection limit (\\< 20 pg/mL) in all participants studied.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Serum IL-4 levels were below detection limit (\\< 20 pg/mL) in all participants studied.","groupId":"OG002","spread":"NA","value":"NA"}]}],"title":"IL-4: Cycle 2 Week 1 (N=0, 0, 0)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"description":"The activation of immune effector cells was monitored by the measurement of peripheral blood cytokine levels including interleukin (IL)-2, IL-4, IL-6, IL-10, tumor necrosis factor-alpha (TNF-α) and interferon gamma (IFN-ɣ) using cytometric bead assays. The limit of detection of the assay (LOD) was 20 pg/mL and the lower limit of quantification (LLOQ) was 125 pg/mL. Data below LOD were set to 10 pg/mL while data \\< LOQ and \\> LOD were reported as measured.","dispersionType":"Standard Deviation","groups":[{"description":"Blinatumomab was administered as a continuous intravenous infusion at a constant daily flow rate of 5 µg/m²/day..","id":"OG000","title":"Phase 1: Blinatumomab 5 µg/m²/Day"},{"description":"Blinatumomab was administered as a continuous intravenous infusion at a constant daily flow rate of 15 µg/m²/day.","id":"OG001","title":"Phase 1: Blinatumomab 15 µg/m²/Day"},{"description":"Blinatumomab was administered as a continuous intravenous infusion at a constant daily flow rate of 30 µg/m²/day.","id":"OG002","title":"Phase 1: Blinatumomab 30 µg/m²/Day"}],"paramType":"MEAN","populationDescription":"Phase 1 full analysis set participants with available data","reportingStatus":"POSTED","timeFrame":"Cycle 1 and 2 day 1 (prior to infusion, 2 and 6 hours after infusion start), day 2 and day 3.","title":"Serum Cytokine Peak Levels","type":"SECONDARY","unitOfMeasure":"pg/mL"}